PhaseBio Pulls Plug On Mid-Stage Hypertension Asset
PhaseBio's Shares Slide As Antiplatelet Candidate Shows Higher Rates Of Side Effect
PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study
5 Penny Stocks To Watch For November With Potential Biotech Catalysts